This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.To describe late outcomes over time in relation to survival, growth, neurologic, and neuropsychological function, quality of life, organ system toxicity, metabolic disorders, development of oppotunistic infections and malignancies, and immunologic, and virologic parameters in HIV-infected infants, children, and adolescents. This will also include evaluation of potential late effects, impact of puberty, and complications of antiretroviral and immune therapy received by the subject. This study will also attempt to determine if uninfected infants born to HIV-infected women demonstrate any short or long-term adverse clinical or laboratory effects due to exposure to antiretroviral therapy or immune therapy/vaccines in utero, the perinatal period, or early infancy. This is a perspective, longitudinal study for long term follow-up of perinatally HIV-exposed infants, children, and adolescents, and children with post-perinatally acquired infection followed at PACTG site regardless of whether they are enrolled in PACTG protocols. The purpose of this study is to describe late outcomes over time in relation to survival, growth, neurologic and neuropsychologic function, quality of life, organ system toxicity, metabolic disorders, development of opportunistic infections and malignancies, and immunilogical, and virologic parameters in HIV-infected infants, children and adolescents. This will also include evaluation of potential late outcomes, impact of puberty, and complications of antiretroviral and immune therapy received by the subject. Moreover, to determine if uninfected infants born to HIV-infected women demonstrate any short or long term adverse clinical or laboratory effects due to exposure to antiretroviral therapy or immune therapy/vaccines in utero, the perinatal period, or early infancy.
Showing the most recent 10 out of 203 publications
